📬 Subscribe for monthly updates | 🔍 Browse topics
We track breakthroughs in aging and longevity from around the world — giving credit where it's due, without hype, bias, or commercial interest.
📡 Updated monthly. Free for everyone.
One short email per month. No spam. Unsubscribe anytime.
🆕 May 31, 2026 – What is coming up
What's new this month
🕊️ May 2026 — In Progress
Next full archive update: May 31. This month we're tracking emerging organogenesis platforms, new senolytic trials, and AI-discovered biomarkers.
📢 Update — May 4, 2026: The OSK trial has completed enrollment. Safety data expected Q4 2026. Source →
⚡ FAST WATCH — updated weekly
Not yet peer-reviewed, but worth following:
- May 19: Closed‑loop vascular cleaning for atherosclerosis — proposal to isolate an artery segment, drain blood, and circulate plaque‑dissolving chemicals (EDTA, surfactants, collagenase). Solves toxicity + embolism problems but has not been tested in animals or humans. Hypothesis only. Source →
- May 18: Stem cells for human longevity — no lifespan data in healthy humans. MSC trials for osteoarthritis and frailty are ongoing; evidence is promising but early. Partial reprogramming (OSK) is distinct, already in Phase I human trials. Source →
- May 17: Glymphatic system clears Alzheimer's proteins (Aβ, tau) from brain to plasma in humans — randomized crossover trial (n=39) found normal sleep increased morning plasma AD biomarkers compared to sleep deprivation, confirming sleep‑active clearance. First causal human evidence. Source →
- May 16: NG101 antibody therapy for acute spinal cord injury — Phase 2b trial (n=106) showed visible MRI healing, reduced lesions, and signs of nerve regrowth by blocking Nogo-A protein. First evidence of structural spinal cord repair in humans. Source →
- May 10: AI‑designed Parkinson's drug (ISM8969, NLRP3 inhibitor) received FDA IND clearance for Phase I safety trial — in healthy volunteers, not yet patients. Preclinical: anti‑inflammatory, crosses blood‑brain barrier. Source →
- May 10: Anktiva (N-803, nogapendekin alfa inbakicept) – IL-15 superagonist activating NK cells. FDA‑approved for BCG‑unresponsive bladder cancer (2024). Saudi FDA approved for metastatic lung cancer (Jan 2026). Not a universal cancer cure. Trials ongoing for breast, pancreatic, glioblastoma. Source →
- May 10: Russian RAGE‑targeting gene therapy for aging — officially announced April 2026. Preclinical stage. Targets RAGE receptor (linked to inflammation/aging). Production goal 2028–2030. No human trials yet. Political context matters. Source →
- May 7: New senolytic candidate from AI screen (preprint) — summary & citation
- May 4: OSK trial enrollment complete — update
📬 Full citations added to monthly archive when peer-reviewed. Subscribe for the monthly digest.
📬 All existing content from April 14 remains. These are additions — nothing removed, nothing repeated.
Browse by topic
🧬 Rejuvenation
Reversing or slowing biological age — epigenetic reprogramming, senolytics, gene therapy, partial reprogramming (global).
💊 Therapeutics
Drugs, supplements, clinical trials — metformin, rapamycin, fisetin, new senolytics, AI‑discovered compounds (global).
🧠 Cognitive Longevity
Brain health, dementia, mental aging — Alzheimer's research, light/sound therapy, nootropics, brain fog (global).
🌍 Exposome & Lifestyle
Environment, diet, exercise, social factors — pollution, sleep, stress, autonomic balance (global).
🤖 AI & Longevity
Artificial intelligence in aging research — AI drug discovery, predictive models, biomarker identification (global).
📊 Biomarkers & Diagnostics
Measuring aging — epigenetic clocks, piRNAs, blood tests, imaging (global).
🩺 Clinical Trials & Regulatory
Human studies, approvals, safety — Phase I/II/III trials, FDA approvals, TAME trial, OSK therapy (global).